Cite
HARVARD Citation
Amiot, A. et al. (2017). One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Alimentary pharmacology & therapeutics. 46 (3), pp. 310-321. [Online].